Goldman Sachs analyst Salveen Richter reiterated a Neutral rating and $47.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE